© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
RxSight, Inc. (RXST) stock surged +0.08%, trading at $6.09 on NASDAQ, up from the previous close of $6.08. The stock opened at $6.03, fluctuating between $5.94 and $6.15 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 06, 2026 | 6.00 | 6.13 | 5.43 | 6.08 | 1.34M |
| Aug 05, 2026 | 6.17 | 6.38 | 6.01 | 6.29 | 901.43K |
| Aug 04, 2026 | 6.28 | 6.43 | 6.16 | 6.25 | 645.39K |
| Aug 03, 2026 | 6.10 | 6.34 | 6.07 | 6.29 | 1.23M |
| Jul 31, 2026 | 6.08 | 6.12 | 5.86 | 6.01 | 540.87K |
| Jul 30, 2026 | 6.14 | 6.22 | 5.93 | 6.08 | 509.86K |
| Jul 29, 2026 | 6.00 | 6.23 | 5.84 | 6.13 | 934.7K |
| Jul 28, 2026 | 5.64 | 6.07 | 5.64 | 6.05 | 1.33M |
| Jul 27, 2026 | 5.25 | 5.68 | 5.25 | 5.64 | 984.1K |
| Jul 24, 2026 | 5.40 | 5.47 | 5.06 | 5.19 | 842.71K |
| Jul 23, 2026 | 5.28 | 5.41 | 5.23 | 5.37 | 781.68K |
| Jul 22, 2026 | 5.26 | 5.42 | 5.10 | 5.39 | 841.89K |
| Jul 21, 2026 | 5.52 | 5.59 | 5.18 | 5.25 | 1.52M |
| Jul 20, 2026 | 5.51 | 5.63 | 5.40 | 5.61 | 747.37K |
| Jul 17, 2026 | 5.48 | 5.73 | 5.38 | 5.55 | 839.14K |
| Jul 16, 2026 | 5.06 | 5.93 | 5.06 | 5.57 | 2.37M |
| Jul 15, 2026 | 4.91 | 5.31 | 4.86 | 5.25 | 738.8K |
| Jul 14, 2026 | 5.06 | 5.13 | 4.84 | 4.92 | 748.62K |
| Jul 13, 2026 | 4.93 | 5.25 | 4.88 | 5.06 | 782K |
| Jul 10, 2026 | 5.08 | 5.11 | 4.88 | 4.95 | 690.44K |
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
| Employees | 461 |
| Beta | 1.15 |
| Sales or Revenue | $89.08M |
| 5Y Sales Change% | 30.867% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |